706 related articles for article (PubMed ID: 10663363)
21. The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures.
Hadji P; Zanchetta JR; Russo L; Recknor CP; Saag KG; McKiernan FE; Silverman SL; Alam J; Burge RT; Krege JH; Lakshmanan MC; Masica DN; Mitlak BH; Stock JL
Osteoporos Int; 2012 Aug; 23(8):2141-50. PubMed ID: 22159672
[TBL] [Abstract][Full Text] [Related]
22. The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis.
Brown JP; Kendler DL; McClung MR; Emkey RD; Adachi JD; Bolognese MA; Li Z; Balske A; Lindsay R
Calcif Tissue Int; 2002 Aug; 71(2):103-11. PubMed ID: 12085156
[TBL] [Abstract][Full Text] [Related]
23. Risedronate once a week.
White NJ; Perry CM
Treat Endocrinol; 2003; 2(6):415-20; discussion 421. PubMed ID: 15981945
[TBL] [Abstract][Full Text] [Related]
24. Fracture risk remains reduced one year after discontinuation of risedronate.
Watts NB; Chines A; Olszynski WP; McKeever CD; McClung MR; Zhou X; Grauer A
Osteoporos Int; 2008 Mar; 19(3):365-72. PubMed ID: 17938986
[TBL] [Abstract][Full Text] [Related]
25. Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: greater increases in bone mineral density do not relate to greater decreases in fracture risk.
Watts NB; Cooper C; Lindsay R; Eastell R; Manhart MD; Barton IP; van Staa TP; Adachi JD
J Clin Densitom; 2004; 7(3):255-61. PubMed ID: 15319494
[TBL] [Abstract][Full Text] [Related]
26. Risedronate for the prevention and treatment of postmenopausal osteoporosis: results from recent clinical trials.
Watts NB
Osteoporos Int; 2001 Dec; 12 Suppl 3():S17-22. PubMed ID: 11846337
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of risedronate administration in osteoporotic postmenopausal women affected by inflammatory bowel disease.
Palomba S; Orio F; Manguso F; Falbo A; Russo T; Tolino A; Tauchmanovà L; Colao A; Doldo P; Mastrantonio P; Zullo F
Osteoporos Int; 2005 Sep; 16(9):1141-9. PubMed ID: 15928801
[TBL] [Abstract][Full Text] [Related]
28. Risedronate reduces the risk of first vertebral fracture in osteoporotic women.
Heaney RP; Zizic TM; Fogelman I; Olszynski WP; Geusens P; Kasibhatla C; Alsayed N; Isaia G; Davie MW; Chesnut CH
Osteoporos Int; 2002; 13(6):501-5. PubMed ID: 12107665
[TBL] [Abstract][Full Text] [Related]
29. Risedronate: a clinical review.
Crandall C
Arch Intern Med; 2001 Feb; 161(3):353-60. PubMed ID: 11176760
[TBL] [Abstract][Full Text] [Related]
30. The efficacy and tolerability of risedronate on bone mineral density and bone turnover markers in osteoporotic Chinese women: a randomized placebo-controlled study.
Leung JY; Ho AY; Ip TP; Lee G; Kung AW
Bone; 2005 Feb; 36(2):358-64. PubMed ID: 15780963
[TBL] [Abstract][Full Text] [Related]
31. Risedronate increases bone mineral density and reduces the vertebral fracture incidence in postmenopausal women.
Reginster JY
Clin Exp Rheumatol; 2001; 19(2):121-2. PubMed ID: 11326471
[No Abstract] [Full Text] [Related]
32. Prevention of bone loss and vertebral fractures in patients with chronic epilepsy--antiepileptic drug and osteoporosis prevention trial.
Lazzari AA; Dussault PM; Thakore-James M; Gagnon D; Baker E; Davis SA; Houranieh AM
Epilepsia; 2013 Nov; 54(11):1997-2004. PubMed ID: 24010637
[TBL] [Abstract][Full Text] [Related]
33. Use of matched historical controls to evaluate the anti-fracture efficacy of once-a-week risedronate.
Watts NB; Lindsay R; Li Z; Kasibhatla C; Brown J
Osteoporos Int; 2003 Jun; 14(5):437-41. PubMed ID: 12730756
[TBL] [Abstract][Full Text] [Related]
34. A comparison of the effect of risedronate and etidronate on lumbar bone mineral density in Japanese patients with osteoporosis: a randomized controlled trial.
Fukunaga M; Kushida K; Kishimoto H; Shiraki M; Taketani Y; Minaguchi H; Inoue T; Morita R; Morii H; Yamamoto K; Ohashi Y; Orimo H;
Osteoporos Int; 2002 Dec; 13(12):971-9. PubMed ID: 12459940
[TBL] [Abstract][Full Text] [Related]
35. Risedronate preserves bone architecture in early postmenopausal women in 1 year as measured by three-dimensional microcomputed tomography.
Dufresne TE; Chmielewski PA; Manhart MD; Johnson TD; Borah B
Calcif Tissue Int; 2003 Nov; 73(5):423-32. PubMed ID: 12964065
[TBL] [Abstract][Full Text] [Related]
36. Sustained efficacy of risedronate in men with primary and secondary osteoporosis: results of a 2-year study.
Ringe JD; Farahmand P; Faber H; Dorst A
Rheumatol Int; 2009 Jan; 29(3):311-5. PubMed ID: 18762944
[TBL] [Abstract][Full Text] [Related]
37. Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women.
Wells G; Cranney A; Peterson J; Boucher M; Shea B; Robinson V; Coyle D; Tugwell P
Cochrane Database Syst Rev; 2008 Jan; (1):CD004523. PubMed ID: 18254053
[TBL] [Abstract][Full Text] [Related]
38. Effectiveness of risedronate in osteoporotic postmenopausal women with inflammatory bowel disease: a prospective, parallel, open-label, two-year extension study.
Palomba S; Manguso F; Orio F; Russo T; Oppedisano R; Sacchinelli A; Falbo A; Tolino A; Zullo F; Mastrantonio P
Menopause; 2008; 15(4 Pt 1):730-6. PubMed ID: 18698280
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of risedronate 150-mg once a month in the treatment of postmenopausal osteoporosis: 2-year data.
McClung MR; Zanchetta JR; Racewicz A; Roux C; Benhamou CL; Man Z; Eusebio RA; Beary JF; Burgio DE; Matzkin E; Boonen S; Delmas P
Osteoporos Int; 2013 Jan; 24(1):293-9. PubMed ID: 22752050
[TBL] [Abstract][Full Text] [Related]
40. Risedronate on 2 consecutive days a month reduced vertebral fracture risk at 1year compared with historical placebo.
Watts NB; Brown JP; Cline G
J Clin Densitom; 2010; 13(1):56-62. PubMed ID: 19942469
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]